Case reports have shown that patients with psoriasis treated with IL-17A antagonists, including secukinumab and ixekizumab, showed relatively mild disease or were asymptomatic when they were infected with SARS-CoV-2 [26,27,28,29]. The gene discussed is IL17A; the disease is psoriasis.